Spherix’s inaugural Patient Dynamix™: IgAN research, focusing on real-world patient experiences, reveals unmet needs in disease education, affordability, and care
Gastroenterologists are enthusiastic about Tremfya’s subcutaneous induction option in Crohn’s disease, a key potential brand differentiator, according to Spherix Global
While interest in BMS’s pipeline asset is strong, some prescribers are underwhelmed by ACR20 endpoint. EXTON, PA, March 27, 2025
Exton, PA, March 27, 2025 – Tucker Hurtado, Vice President of Product Planning at Spherix Global Insights, has been named
As the IgAN market expands with the introduction of branded therapies, nephrologists express growing interest in the early-line potential of
Hematologists remain undecided on the long-term role of newly launched hemophilia therapies, particularly as the industry awaits word on Sanofi’s
AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch
Latest independent research from Spherix Global Insights highlights growing urgency to treat PNH with complement or factor inhibitors, shifting physician
Vafseo is currently only approved in dialysis patients with chronic kidney disease-related anemia thanks to safety concerns raised by the
In the plaque psoriasis arena, Sotyktu is facing off against Amgen’s Otezla and is facing the threat of upcoming competition
Formalizing a longstanding collaboration to unite patient advocacy and market expertise to drive advancements in kidney patient care. EXTON, PA.,
There are signs Bimzelx is affecting the psoriatic arthritis market. UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global
